The evolution of bispecific antibodies in multiple myeloma
Rattachement africain : fr, lb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
The treatment of multiple myeloma (MM) has revolutionized over the last decade with the advent of CD38-targeting monoclonal antibodies such as daratumumab and isatuximab that were integrated into the therapeutic arsenal of patients with newly diagnosed or with relapsed and/or refractory (R/R) MM. Moreover, the advent of B-cell maturation antigen (BCMA)-targeting therapy continue to improve outcomes in patients with R/R disease. Multiple classes of these agents have been developed such as chimeric antigen receptor (CAR)-T cell therapy and antibody-drug conjugates. Another class of antigen-target therapy was the bispecific antibodies (BsAbs). The class, targeting CD20 and CD3, is now commonly used in patients with R/R B-cell lymphoma. It has also been developed for the treatment of patients with MM with other target antigens such BCMA, G protein-coupled receptor family C group 5 member D (GPRC5D), or Fc receptor-homolog 5 (FcRH5). Four BsAbs-teclistamab, elranatamab, linvoseltamab, and talquetamab-are currently approved by the Food and Drug Administration (FDA) for the management of patients with R/R MM. We review in this paper the most studied BiAbs, their mechanism of action, clinical activity, the mechanism of resistance. We discuss the place of BiAbs in the therapeutic arsenal of MM and the emergence of novel strategies such as combining two classes of BiAbs (for example teclistamab and talquetamab) or novel therapies such as trispecific antibodies to overcome resistance and increase the efficacy of BiAbs.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The evolution of bispecific antibodies in multiple myeloma
- Date Crossref
- 01/02/2026
- Éditeur
- AME Publishing Company
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Institut Gustave Roussy pays non établi dans la noticeStructure de recherche
-
University Medical Center Rizk Hospital pays non établi dans la noticeÉtablissement de santé
-
International Department pays non établi dans la noticeInstitution
-
Department of Head and Neck Oncology pays non établi dans la noticeInstitution
-
Department of Biopathology pays non établi dans la noticeInstitution
-
Lebanese American University Rizk Hospital Hematology and Medical Oncology Department pays non établi dans la noticeUniversité ou école supérieure
Institut Gustave Roussy, University Medical Center Rizk Hospital et International Department, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.